Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.74 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | GLA | P06280 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | RECQL | P46063 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.67 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.67 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.67 |
| ▸ | GMNN | O75496 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343717 | 0.88 | NPBWR1 (0.59) | NPBWR1DGAT1KCNH2MEN1KMT2A | |
| SCHEMBL6325961 | 0.88 | NPBWR1 (0.59) | NPBWR1DGAT1KCNH2MEN1KMT2A | |
| SCHEMBL529750 | 0.85 | NPBWR1 (0.74) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL10381149 | 0.85 | NPBWR1 (1.00) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL4184260 | 0.85 | DGAT1 (1.00) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL900794 | 0.85 | NPBWR1 (0.74) | NPBWR1DGAT1KCNH2SOAT1MMP2 | |
| SCHEMBL20445295 | 0.85 | NPBWR1 (1.00) | NPBWR1DGAT1KCNH2MEN1KMT2A | |
| SCHEMBL30726446 | 0.85 | NPBWR1 (0.72) | NPBWR1DGAT1KCNH2MEN1KMT2A | |
| SCHEMBL27040128 | 0.85 | NPBWR1 (0.72) | NPBWR1DGAT1KCNH2MEN1KMT2A | |
| SCHEMBL363703 | 0.82 | MEN1 (1.00) | NPBWR1MEN1KMT2ARXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277686-A1 | Benzimidazole compounds for regulating IgE | SIRCAR JAGADISH C | 2005-12-15 | — | — | US | disclosed |
| US-6911462-B2 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS | 2003-05-29 | — | — | US | disclosed |
| US-6369091-B1 | ANTIALLERGENS | AVANIR PHARMACEUTICALS | 2002-04-09 | — | — | US | disclosed |
| EP-1079830-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | Avanir Pharmaceuticals (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061020-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | NPBWR1 1002/4885DGAT1 1527/4885KCNH2 3242/4885 |
| US-20050277686-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | NPBWR1 1002/4885DGAT1 1527/4885KCNH2 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.